Lecanemab-irmb: A Treatment Option for the Early Stages of Alzheimer’s Disease
Target Audience: Pharmacy Tech
Course Overview
Over 55 million people are living with dementia worldwide and this number is expected to grow. The projections are that by 2050, the number of people with Alzheimer’s disease (AD) dementia will triple. These staggering numbers highlight the need for the development of new treatments for patients with AD. Lecanemab-irmb is a newly approved drug for AD patients with mild cognitive impairment or mild dementia. Further trials are needed to confirm the efficacy and safety of lecanemab in early AD. Pharmacy teams are well-positioned to discuss lecanemab-irmb with healthcare professionals and patients suffering from AD.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Describe the basic pathophysiology associated with Alzheimer's disease
- Describe the proper indications and uses of lecanemab-irmb
- Identify possible adverse effects associated with the use of lecanemab-irmb
- Provide information to patients and caregivers about support and resources for Alzheimer’s patients
Faculty
I. Introduction
II. The History of Alzheimer’s Disease
III. Prevalence of Alzheimer’s Disease
IV. Pathophysiology in Mild Alzheimer’s Disease
V. New Pharmacotherapy Option: Lecanemab-irmb
1. Mechanism of Action
2. Dosing
3. Clinical Trials
4. Adverse Events
VI. Patient and Caregiver Education and Resources
VII. What Is Next?
VIII. Summary
From February 21, 2023 through February 21, 2026, participants must:
- Read the "learning objectives" and "author and planning team disclosures"
- Study the section entitled "educational activity"
- Complete the Course Test and Evaluation form. The Course Test will be graded automatically. Following successful completion of the Course Test with a score of 70% or higher, a statement of participation will be made available immediately. (No partial credit will be given.)
Credit for this course will be automatically uploaded to CPE Monitor®.
Faculty Planner Disclosure
The following individuals were involved in the development of this activity: Pamela Sardo, PharmD, B.S., and Susan DePasquale, MSN, PMHNP-BC. Pamela Sardo, Pharm.D., B.S., was an employee of Rhythm Pharmaceuticals until March 2022 and has no conflicts of interest or relationships regarding the subject matter discussed. There are no financial relationships relevant to this activity to report or disclose by any of the individuals involved in the development of this activity.
Unlabeled Use Disclosure
The information provided in this course is general in nature and it is solely designed to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice. Healthcare professionals, including pharmacists and pharmacy technicians, must consult with their employer, healthcare facility, hospital, or other organization, for guidelines, protocols, and procedures they are to follow. The information provided in this course does not replace those guidelines, protocols, and procedures but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits. Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses are constantly changing, and any person taking this course understands that such person must make an independent review of medication information prior to any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only and such uses are not endorsed hereby. Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course, or course material.
Please ensure the device you plan to use meets these requirements:
- Operating System: Windows 7, 8, 10, or 11 / Mac OS X 10.9 or later / iOS / Android
- Supported Browsers: Microsoft Edge, Firefox, Google Chrome, Safari, Opera
- A connection to the internet
Accreditation
In support of improving patient care, RxCE.com is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PTCB Recognition
RxCe.com, LLC, offers pharmacy technician continuing education courses for PTCB recertification. Pharmacy technician courses are indicated both in the Target Audience description and the ACPE UAN which will end with a "T".